scispace - formally typeset
R

Rongshan Li

Researcher at Tianjin Medical University

Publications -  12
Citations -  592

Rongshan Li is an academic researcher from Tianjin Medical University. The author has contributed to research in topics: Pullulan & Drug carrier. The author has an hindex of 10, co-authored 12 publications receiving 468 citations.

Papers
More filters
Journal ArticleDOI

Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.

TL;DR: In HepG2 tumor-bearing mice, CAPL/PBAE/PLGA nanoparticles showed excellent tumor-targeting capability and remarkably increased inhibitory effects of PTX and CA4 on tumor growth and angiogenesis, and this novel nanoparticle system is a promising candidate as carrier for drugs against HCC.
Journal ArticleDOI

pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma

TL;DR: This drug carrier system has significant liver-targeting property and exhibits advantages for the combination therapy against hepatocellular carcinoma.
Journal ArticleDOI

Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel carrier for paclitaxel

TL;DR: Results suggest that CCMC-6.9 self-assembled nanoparticles can effectively solubilize PTX and modify its tissue biodistribution, which may be advantageous in enhancing the therapeutic index and reducing the toxicity of PTX.
Journal ArticleDOI

Macromolecular crowding of molecular imprinting: A facile pathway to produce drug delivery devices for zero-order sustained release.

TL;DR: The results indicated that the MMC condition can modulate the polymer networks approaciate to zero-order release of the drug and maintain the molecular memory pockets, even if under the poor polymerization conditions of MIPs preparation.
Journal ArticleDOI

pH-sensitive pullulan-based nanoparticle carrier for adriamycin to overcome drug-resistance of cancer cells.

TL;DR: The results of flow cytometry and confocal microscopy showed that URPA nanoparticles efficiently enhanced accumulation and retention of ADR in MCF-7/ADR cells and successfully delivered ADR into cell nucleus.